Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MW02 versus ranibizumab for neovascular age-related macular degeneration
CTR20202561Phase 3Completed
- Sponsor
- Jiangsu T-mab Biopharma Co., Ltd.
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of MW02 in exudative macular degeneration, sponsored by Jiangsu T-mab Biopharma Co., Ltd.. Started May 2021; status: completed.
02
Drugs
MW02
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20202561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202561.